No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

VentureMed FLEX Vessel Prep™ System 12-Month Data To Be Presented at VEITHsymposium 2022 in PAD with DCB’s and AV Access Management

Editor: What To Know

  • , a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced new data presentations in peripheral artery disease (PAD) with DCB’s in addition to 12-month AV Registry Data.
  • Data presented will cover the use of FLEX Vessel Prep System in both PAD treatment with DCB and also in AV access interventions.
  • develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of stenoses of AV fistulas and grafts and PAD.

VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced new data presentations in peripheral artery disease (PAD) with DCB’s in addition to 12-month AV Registry Data. These presentations will be given as part of the VEITHsymposium Annual Scientific Meeting 2022. The congress will take place in New York, New York from November 15-19th.

Data presented will cover the use of FLEX Vessel Prep System in both PAD treatment with DCB and also in AV access interventions. The AV Access presentation will expand the 6-month AV Registry data presented at VASA in June with 12-month results.

The two presentations are as follows:

Late Breaking Trial with FLEX Vessel Prep and DCB’s Show Better 12-Month Results With FemPop
Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM
Director | Vascular Intervention | Beth Israel Deaconess Medical Center 
Section Head | Interventional Cardiology and Vascular Research | Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology | Beth Israel Deaconess Medical Center
Assistant Professor of Medicine| Harvard Medical School.
Saturday November 19 6:55am EST

FLEX Vessel Prep System: Clinical Outcomes And Utility In HD Access Practice – AV Registry 12-Month Study Results
John E. Aruny, MD
Primary Investigator,
Dialysis Access Institute,
Orangeburg, SC.
Saturday November 19, 8:22am EST

About VentureMed Group, Inc., and the FLEX Vessel Prep™ System” The VentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of stenoses of AV fistulas and grafts and PAD. The FLEX VP™ System is a unique, non-balloon-based approach to optimizing revascularization by creating long controlled-depth micro-incisions that release circumferential tension to improve vessel compliance and enable luminal gain with less vessel trauma that may cause restenosis. FLEX was designed to provide controlled and predictable pre-treatment to optimize outcomes in complex stenoses & lesions of any length or vessel morphology. The FLEX VP System received CE Mark and 510(k) clearance from the US Food and Drug Administration.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy